ストックスクリーナーアプリを入手
24.81
6.87%
-1.83
前日終値:
$26.64
開ける：
$26.35
24時間の取引高:
221.43K
Relative Volume:
0.65
時価総額：
$1.89B
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-15.03%
1か月 パフォーマンス:
-32.40%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$22.51
$28.10
1週間の範囲:
$22.51
$29.30
52週間の値動き範囲:
$9.95
$67.00
Jyong Biotech Ltd Stock (MENS) Company Profile
MENS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MENS
Jyong Biotech Ltd
|
24.81 | 2.03B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Jyong Biotech Ltd (MENS) 最新ニュース
Jyong Biotech Shares Becomes Oversold (MENS) - Nasdaq
Jyong Biotech (NASDAQ:MENS) Trading Down 5.9%Here's Why - MarketBeat
Jyong Biotech Ltd.’s (NASDAQ:MENS) Lock-Up Period Will End on December 15th - Defense World
Jyong Biotech (NASDAQ:MENS) Shares Gap Down – Here’s Why - Defense World
Taiwan's Jyong Biotech expands regional partnership with MoU signing in Vietnam - BioSpectrum Asia
Jyong Biotech (NASDAQ:MENS) Stock Price Down 4.3%Time to Sell? - MarketBeat
Jyong Biotech expands regional partnerships, signs MoU with a Vietnam pharmaceutical distributor - marketscreener.com
Jyong Biotech Expands Regional Partnerships, Signs MoU With A Vietnam Pharmaceutical Distributor - TradingView
Jyong Biotech Expands Regional Partnerships, Signs MOU with - GlobeNewswire
Jyong Biotech (NASDAQ:MENS) Shares Gap UpWhat's Next? - MarketBeat
Jyong Biotech (MENS) Stock Analysis Report | Financials & Insights - Benzinga
Jyong Biotech (NASDAQ:MENS) Trading Up 15.1%Here's What Happened - MarketBeat
Jyong Biotech: Speculative BPH And Prostate Cancer Prevention Story (NASDAQ:MENS) - Seeking Alpha
Jyong Biotech (NASDAQ:MENS) Stock Price Down 9.6%What's Next? - MarketBeat
Taiwan's Jyong Biotech announces partnership in Korea to evaluate in‑licensing of plant-derived MCS drugs - BioSpectrum Asia
Jyong Biotech signs letter of intent with South Korean pharma company - Investing.com Australia
Jyong Biotech to Evaluate Licensing Deal for MCS-2 Drug Candidate in South Korea - marketscreener.com
Jyong Biotech signs letter of intent with South Korean pharma company By Investing.com - Investing.com South Africa
Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs - The Manila Times
Jyong Biotech (Nasdaq: MENS) LOI to Evaluate MCS-2 Licensing with Korean Pharma - Stock Titan
Jyong Biotech (NASDAQ:MENS) Shares Up 10.9%Should You Buy? - MarketBeat
Jyong Biotech completes primary endpoint analysis for Phase II trial of MCS-8 - Yahoo Finance
Exploring Jyong Biotech’s (NasdaqGM:MENS) Valuation Following Recent Share Price Volatility - Yahoo Finance
Jyong Biotech reports positive results for prostate cancer drug in phase II trial - Investing.com Nigeria
Jyong Biotech stock soars after positive Phase II prostate cancer drug results - Investing.com Nigeria
Jyong Biotech stock soars after positive Phase II prostate cancer drug results By Investing.com - Investing.com South Africa
Jyong Biotech Says Phase 2 Trial of MCS-8 in Prostate Cancer Meets Efficacy Endpoints - marketscreener.com
Jyong Biotech announces completion of primary endpoint statistical analysis for phase II clinical trial of MCS-8 with positive outcomes - MarketScreener
Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes - The Manila Times
Jyong Biotech Announces Completion of Primary Endpoint - GlobeNewswire
Jyong Biotech (Nasdaq: MENS) MCS-8 Phase II Cuts Prostate Cancer 27%, High-Grade 17% - Stock Titan
Jyong Biotech (NASDAQ:MENS) Shares Gap DownTime to Sell? - MarketBeat
Jyong Biotech Ltd. (MENS) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Jyong Biotech is Now Oversold (MENS) - Nasdaq
Jyong Biotech plunges 49% after InvestingPro’s overvalued warning By Investing.com - Investing.com Australia
Google, Alibaba among market cap stock movers on Monday - Investing.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Google and Micron among market cap stock movers on Monday By Investing.com - Investing.com UK
Google and Micron among market cap stock movers on Monday - Investing.com India
Jyong Biotech (MENS US): Taiwan-Based, US-Listed, Excluded from US & Global Indices - Smartkarma
Jyong Biotech (NASDAQ:MENS) Trading Down 8%Here's Why - MarketBeat
Dow notches record-high close while tech-heavy Nasdaq slips - Yahoo Finance
Dow notches record high close, traders bet on end to shutdown - Yahoo Finance
Health insurers slide after subsidies dropped from US shutdown deal - Yahoo Finance
Global shares jump as investors eye potential end to US shutdown - Yahoo Finance
Wall Street ends higher on solid data, strong earnings - Yahoo Finance
Jyong Biotech Ltd (MENS) 財務データ
Jyong Biotech Ltd (MENS) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.08%
0.91%
大文字化:
|
ボリューム (24 時間):